💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tranylcypromine

CHEMBL3989843 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
133.2 g/mol
LogP
1.5
Phase
4

Tranylcypromine is an irreversible, non-selective monoamine oxidase (MAO-A and MAO-B) inhibitor that prevents the oxidative deamination of serotonin, norepinephrine, dopamine, and tyramine, increasing central monoamine levels and producing antidepressant and anxiolytic effects. It is used for treatment-resistant major depression, particularly atypical depression and social anxiety disorder with comorbid depression. Patients must follow strict dietary tyramine restrictions due to the risk of hypertensive crisis from impaired tyramine metabolism.

आणविक भार

133.1900 g/mol

LogP

1.50

TPSA

26.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर बाइपोलर डिसऑर्डर मेजर डिप्रेसिव डिसऑर्डर मोटापा ल्यूकेमिया सिज़ोफ्रेनिया स्ट्रोक

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1

                

                

                
                

                    
InChI

                    
InChI=1S/2C9H11N/c2*10-9-6-8(9)7-4-2-1-3-5-7/h2*1-5,8-9H,6,10H2/t2*8-,9+/m10/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H11N

                    

                    
                    

                        
HBD / HBA

                        
1 / 1

                    

                    
                    

                        
घूर्णनीय बंधन

                        
1

                    

                    
                    
                    

                        
भारी परमाणु

                        
10

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
Tranylcypromine is an irreversible, non-selective monoamine oxidase (MAO-A and MAO-B) inhibitor that prevents the oxidative deamination of serotonin, norepinephrine, dopamine, and tyramine, increasing central monoamine levels and producing antidepressant and anxiolytic effects. It is used for treatment-resistant major depression, particularly atypical depression and social anxiety disorder with comorbid depression. Patients must follow strict dietary tyramine restrictions due to the risk of hypertensive crisis from impaired tyramine metabolism.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Tranylcypromine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3989843.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5530.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.